SuppreMol appoints industry expert Michael Tansey as Chief Development Officer

SuppreMol GmbH / SuppreMol appoints industry expert Michael Tansey as Chief Development Officer . Ad hoc announcement according to § 15 WpHG. Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. Munich, Germany, September 10(th), 2013: SuppreMol GmbH, a privately held biopharmaceutical company developing novel therapies for the treatment of autoimmune diseases, today announced the appointment of Dr Michael Tansey as Chief Development Officer (CDO) of the Company. At SuppreMol, Dr Tansey will oversee both the non-clinical and clinical development of the Fc-gamma receptor (FcgR) product family, in particular SM101, which is in Phase II clinical development for Primary Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE). Dr Tansey, who qualified in medicine in 1973, has more than 30 years of successful international clinical development and management experience in the pharmaceutical and biotech industry in Europe, the USA and Asia. He started his career with Hoechst, followed by increasingly responsible roles in Glaxo and Rhone-Poulenc Rohrer, expanding his career in large pharma as Chief Medical Officer and Head of Medical Development at Pharmacia. Since 2003 he has contributed his know-how and experience to several biotechnology companies, including being CMO at NovaCardia and La Jolla Pharmaceutical Company prior to joining SuppreMol. During his career Michael Tansey was involved in the successful clinical development and regulatory approval of more than 15 small molecule and biological products. Dr Klaus Schollmeier, CEO of SuppreMol GmbH, said: "We are very pleased that Dr Tansey is joining our Company at a time when SuppreMol is entering a new and exciting phase. The Company has a very promising product candidate for the treatment of autoimmune diseases in Phase II clinical development with important clinical and regulatory milestones ahead. Dr Tansey brings the necessary experience and knowledge for the Company to successfully advance SuppreMol's clinical programs." "SuppreMol's product candidates are based on innovative science and have shown promising data in early clinical trials for the treatment of diseases for which there is a medical need," stated Dr Michael Tansey, Chief Development Officer at SuppreMol GmbH. "I look forward to spearheading the development of SM101, our lead compound, with the intent of advancing this core asset successfully to the key clinical and regulatory milestones." About SuppreMol SuppreMol GmbH is a privately held biopharmaceutical company developing novel therapeutics for the treatment of autoimmune and allergic diseases. The company is pioneering the development of soluble Fc-gamma receptors (FcgRs), which are recombinant autologous therapeutic proteins with a specific immunoregulatory potential. The company's lead product SM101, a recombinant soluble FcgRIIB is in Phase II clinical development for the treatment of Primary Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) and has potential to treat Rheumatoid Arthritis (RA) and other autoimmune conditions. SuppreMol's pipeline also includes two antibody development programs utilizing the inhibitory effect of FcgRIIB suitable for alternative treatment strategies and indications. SuppreMol was founded as a spin-off from the laboratory of Professor Dr Robert Huber, Nobel Prize Laureate in Chemistry 1988, at the Max Planck Institute for Biochemistry in Martinsried, Germany. To date SuppreMol has raised about € 51 million through private investors. Major shareholders in the company include MIG Fonds, BioMedPartners AG, Santo Holding GmbH and FCP Biotech Holding GmbH along with KfW Mittelstandsbank, Bayern Kapital GmbH, Max Planck Society, and Z-Cube. Contact SuppreMol GmbH Dr Klaus Schollmeier Chief Executive Officer Tel: +49 89 30 90 50 680 E-mail: info@suppremol.com www.suppremol.com Press Release PDF: http://hugin.info/155552/R/1728159/577075.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: SuppreMol GmbH via Thomson Reuters ONE [HUG#1728159]